Medullary thyroid carcinomas (MTC) arise from thyroid parafollicular, calcitonin-producing C-
cells and can occur either as sporadic or as hereditary diseases in the context of familial …

The discovery, isolation, elucidation of structure, synthesis, and initial testing of the
neuropeptide hypothalamic luteinizing hormone‐releasing hormone (LHRH), which …

Degarelix is a gonadotrophin-releasing hormone (GnRH) antagonist for the first-line
treatment of androgen-dependent advanced prostate cancer. It has a direct mechanism of …

Androgens and the androgen receptor play a role in the progression of prostate cancer.
Androgen deprivation therapy (ADT) is a mainstay in the treatment of metastatic prostate …

Androgen deprivation therapy remains the mainstay of medical treatment for advanced
prostate cancer. Commonly, this is achieved with medical androgen deprivation rather than …

OBJECTIVE. The purpose of this article is to provide a comprehensive imaging review of the
common hormonal therapies used in oncology and the side effects associated with them …

Background Androgen deprivation therapy (ADT) has been the standard of care for treating
patients with hormone-sensitive advanced prostate cancer (PCa) for 3 decades. The …

Non‐inferiority in the cumulative castration rate of the 3‐month formulation of degarelix
compared with the 3‐month formulation of goserelin was evaluated in subjects with prostate …

Objectives To assess time to progression to castrate‐resistant prostate cancer (CRPC) and
factors influencing longer‐term outcomes in patients receiving androgen‐deprivation …

Abstract Degarelix (Firmagon®; Gonax®) is a gonadotropin-releasing hormone receptor
antagonist that is approved for the treatment of advanced (hormone-dependent) prostate …